Austar LifesciencesAULSF 49 Days Payable is 110.39 as of Dec. 2025, which is 9% below its 10-year median of 121.30. GuruFocus rates AULSF with a GF Score™ of 49/100 and a GF Value™ of $0.10. The stock has 6 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Austar Lifesciences ranks better than 72.2% on this metric.
The historical rank and industry rank for Austar Lifesciences's Days Payable or its related term are showing as below:
AULSF'
s Days Payable Range Over the Past 10 Years
Min: 76.02 Med: 121.3 Max: 204.32
Current: 122.21
During the past 13 years, Austar Lifesciences's highest Days Payable was 204.32. The lowest was 76.02. And the median was 121.30.
AULSF's Days Payable is ranked better than 72.2% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs AULSF: 122.21
Austar Lifesciences's Days Payable
increased
from Dec. 2024 (107.64) to Dec. 2025 (110.39).
It may suggest that Austar Lifesciencesdelayed paying its suppliers.
Austar Lifesciences Days Payable Related Terms
Austar Lifesciences Days Payable Historical Data
* Premium members only.
The historical data trend for Austar Lifesciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Austar Lifesciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austar Lifesciences Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Austar Lifesciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Austar Lifesciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Austar Lifesciences (AULSF) has a Days Payable of 110.39 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Austar Lifesciences and its competitors. This is near median its historical median of 121.30. Over the past decade, Austar Lifesciences' Days Payable has ranged from 76.02 to 204.32. According to the industry distribution chart, Austar Lifesciences ranks #221 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 27.8%.
Is Austar Lifesciences' Days Payable too high?
Austar Lifesciences' current Days Payable of 110.39 is near median its 10-year median of 121.30. Over the past 10 years, this metric has ranged from a low of 76.02 to a high of 204.32. The Medical Devices & Instruments industry median Days Payable is 68.07. Austar Lifesciences' value of 110.39 is 62.2% above this industry median. Based on the distribution chart, Austar Lifesciences ranks #221 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Austar Lifesciences has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Austar Lifesciences ranks #221 out of 795 companies for Days Payable. This puts Austar Lifesciences in the upper half of its industry. The industry median Days Payable is 68.07. Austar Lifesciences' value of 110.39 is 62.2% above this benchmark. Historically, Austar Lifesciences' own Days Payable has ranged from 76.02 to 204.32 over the past decade. While the company's 10-year median is 121.30 vs. the industry median of 68.07, Austar Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austar Lifesciences's current Days Payable of 110.39 is 62.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Austar Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austar Lifesciences's current Days Payable is 110.39, which is near median its own 10-year median of 121.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Austar Lifesciences (AULSF) has a current Days Payable of 110.39. The stock's GF Value™ is $0.10, compared to a current price of $0.02 — trading 80% below its estimated fair value. The current Days Payable is 110.39, which is near median its 10-year median of 121.30 and 62.2% above the Medical Devices & Instruments industry median of 68.07. Austar Lifesciences' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current Days Payable is 110.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austar Lifesciences (AULSF) Overvalued in 2026?
Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued.
The current stock price of $0.02 is trading 80% below its estimated GF Value™ of $0.10.
Key valuation signals for AULSF:
Days Payable: 110.39 (near median its 10-year median of 121.30)
GF Value™: $0.10 vs. price of $0.02 (80% below fair value)
Industry Position: 62.2% above the Medical Devices & Instruments median (#221 of 795)
No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
49GF Score
Get the complete analysis for AULSF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AULSF has been successfully added to your 
